Search

everythinglearnresearchcommunity

for

Search:↓

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.

A user is seeking information on clinics in Toronto offering dutasteride mesotherapy as an alternative to oral dutasteride while trying to conceive. They are looking for recommendations and information.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

The user switched from finasteride to DIY dutasteride mesotherapy and topical minoxidil due to side effects. They report improved well-being and no hair loss worsening after stopping finasteride.

The conversation discusses finding sources of Dutasteride in Europe for mesotherapy to treat hair loss. It also mentions using Minoxidil, Finasteride, and RU58841 as treatments.

User plans to switch from oral to .005% topical finasteride, using a solvent from minoxidilmax and later Essengen-F. They will monitor DHT levels and seek advice on solvents and sleep caps.

The conversation discusses hair loss treatments, specifically the use of dutasteride, finasteride, and the potential of mesotherapy. The user experiences hair loss despite low DHT levels and considers localized dutasteride treatment, while others suggest consulting a dermatologist and exploring other causes like malabsorption.

Hair mesotherapy with dutasteride is popular in Europe and can be effective, especially when combined with oral dutasteride. Some users suggest using topical dutasteride with microneedling as an alternative, though it may be painful.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

A 35-year-old man shared his hair transplant experience in Tijuana, Mexico, choosing Artline for 5,000 grafts at a lower cost than U.S. clinics. He plans to use topical minoxidil and possibly microneedling for better results.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

A user shared their positive experience and results 10 months after a hair transplant at Mercure Istanbul Clinics, using 3000 grafts. They expressed satisfaction with both the outcome and the clinic's service.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

The conversation is about a user dealing with androgenetic alopecia using minoxidil 5% and attempting to import Adenogen tonic from Japan, which was rejected by Spanish customs. The user seeks advice on obtaining Adenogen or Adenovital within the EU or tips for passing customs.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.